<DOC>
	<DOCNO>NCT02015312</DOCNO>
	<brief_summary>Efficacy safety epigallocatechin-3-gallate ( EGCG ) patient cardiac amyloid light-chain ( AL ) amyloidosis . Evaluation clinical efficacy EGCG intake use pretest posttest comparison leave ventricular amyloid mass ( g/m2 ) measure cardiac MRI .</brief_summary>
	<brief_title>A Trial Treatment Cardiac AL-Amyloidosis With Green Tea Compound Epigallocatechin-3-gallate ( TAME-AL )</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Epigallocatechin gallate</mesh_term>
	<criteria>Biopsy proven systemic AL amyloidosis . Cardiac involvement septum thickness 12 mm ( without cause publish Gertz et al. , hypertension potential cause leave ventricular hypertrophy ) Previously treat chemotherapy , induce least good partial remission underlie monoclonal plasma cell B cell disorder . GPT GOT le 3times ULN . Life expectancy 12 month . Ability subject understand character individual consequence clinical trail . Written informed consent . For woman childbearing potential men , adequate contraception . Age le 18 year . Concomitant multiple myeloma stage 2 3 ( Salmon Durie ) Concurrent chemotherapy necessary Time last chemotherapy 6 month . Chronic liver disease , Bilirubin 1,5 mg/dl Not able visit Amyloidosis Clinic Heidelberg every 3 month . History hypersensitivity investigational product substance similar chemical structure excipient present pharmaceutical form investigational medicinal product . Participation clinical trial observation period compete trial , respectively . Pregnant nursing woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Amyloidosis</keyword>
</DOC>